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In diabetes mellitus a breakdown of the glomerular capillary-
blood barrier with the development of proteinuria (Albustix
positive) is usually accepted as marking the onset of clinical
diabetic nephropathy [I]. This condition progresses, apparently
inexorably, to end-stage renal failure. However, well before
clinical proteinuria becomes evident, an increased rate of the
urinary albumin excretion, as yet undetectable by Albustix
(microproteinuria, Albustix negative), may occur in insulin-
dependent diabetic patients [2]. A clearer understanding of the
characteristics of both microproteinuria and clinical proteinuria
might give insight into the mechanisms responsible for the
altered permeability and suggest possible links between them in
the genesis and evolution of the renal complications of diabetes.
The role of the disturbed metabolic regulation of the diabetic
state in the pathogenesis of diabetic kidney disease can be
examined in the relationship between urinary protein excretion
and differing degrees of glycemia. The availability of new
methods for obtaining radical improvements of blood glucose
control [31 offers an opportunity for direct experimental study
of the stage at which these renal abnormalities can be arrested
or reversed.
This study investigates the urinary excretion rates and the
plasma clearances of different proteins (plasma albumin with
Stokes radius of 36 A, lgG with Stokes radius of 50 A, and 132-
microglobulin with Stokes radius 16 A) in clinically proteinuric
(Albustix positive) insulin-dependent diabetic patients at vari-
ous stages in the evolution of renal failure, in diabetic patients
without clinical proteinuria (Albustix negative), and in normal
control patients. These excretory parameters have been related
to the degree of glycemic control and, in some patients,
restudied after radical correction of blood glucose control.
Methods
The following patients were studied: 27 normal control pa-
tients (21 male, 6 female) ranging in age from 19 to 55 years
(mean, 30.8 years), none with Albustix positive urine, a history
of renal disease or raised BP; 80 normotensive, nonproteinuric
(Albustix negative), insulin-dependent diabetic patients (61
male, 19 female) ranging in age from 15 to 63 years (mean, 35
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years) and duration of diabetes from 2 months to 39 years
(mean, 14.1 years); 23 clinically proteinuric (Albustix pos)
insulin-dependent diabetic patients (17 male, 6 female) ranging
in age from 18 to 60 years (mean, 41.5 years), duration of
diabetes from 12 to 37 years (mean, 19.8 years), and duration of
persistent proteinuria from 1 to 9 years (mean, 3.6 years).
Proteinuria was considered absent when all Albustix readings
during the diabetic clinic visits were found negative over the
period for which the patients had attended Guy's Hospital.
Persistent proteinuria was defined as a positive Albustix at
three or more consecutive diabetic clinic visits. The interval
between visits was usually 3 to 4 months. Nephropathy was
assumed to be diabetic in origin if proteinuria occurred in a
patient with diabetes for more than 10 years, concomitant
retinopathy and no history of other renal disease. No renal
biopsy was performed.
All subjects were within 20% of their ideal body weight [4].
When cultured, their urine proved negative. Nonproteinuric
diabetic and control patients had normal fasting concentrations
of plasma creatinine. Six of the patients with persistent protein-
uria had elevated arterial pressures with pretreatment systolic
values ranging from 152 to 214 mm Hg (mean, 174.6 mm Hg)
and diastolic pressures from 82 to 110 mm Hg (mean, 97 mm
Hg); at the time of the study two patients were on regular
diuretic treatment and one was on beta-blockers. No other
patients were taking regular medications apart from insulin.
Twenty-four-hr urine sample collections were performed at
home or during a stay in the metabolic ward, which was also
used as an opportunity to construct an around-the-clock blood
glucose profile. Urine sample collections in the patients with
clinical proteinuria were made on several occasions as part of a
follow-up study. Nine nonproteinuric diabetic men, ranging in
age from 21 to 52 years (mean, 28.2 years) with a duration of
diabetes from 1.2 to 24 years (mean, 10.8 years) were studied in
random order on two occasions, during conventional insulin
therapy (CIT) and after 3 weeks of near-normoglycemia in-
duced by continuous subcutaneous insulin infusion (CSII) [3].
As part of a prospective study of the influence of glycemic
control on renal function, five proteinuric diabetics (3 male, 2
female), aged between 35 and 60 years (mean, 47.0 years) and
with diabetes 16 to 31 years' (mean, 22.6 years) duration were
also studied during CIT and after 6 months on CSII. Duration of
persistent proteinuria ranged from 2 to 8 years (mean, 5 years).
On CIT mean systolic BP was 148 mm Fig (range 118 to 176 mm
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Fig. 3. Urinary IgG excretion rates, g/min (log scale), in 13 normal
males (•) and in 15 insulin-dependent diabetic men (U).
Table 1. Mean clearance rates SEM (mI/mm/I .73 m2) of albumin,
IgG, and 32-microglobulin in 15 insulin-dependent diabetic men and
13 normal men negative to Albustix
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Fig. 1. Urinary albumin excretion rates, p.g/min (log scale), in27normal
subjects and 80 insulin-dependent diabetic patients negative to A/ba-
stix, separated into duration groups.
Duration of diabetes, years
Fig. 2. Urinary 132-microglobulin excretion rates, ng/min (log scale), in
subjects detailed in Fig. 1.
Hg) and mean diastolic was 91.2 mm Hg (range 76 to 102 mm
Hg). All patients had proliferative retinopathy; one was blind.
BP was measured monthly. When necessary an effort was
made, by the administration of hypotensive therapy, to keep the
BP constant or lower during CSII.
Urinary albumin [5] and 32-microglobulin (Phadebas, P2-
microtest, Pharmacia diagnostics AB, Uppsala, Sweden) con-
centrations were estimated in timed and measured urine vol-
umes in all patients. Urinary IgG (Immunofluor, Bio-Rad Lab.,
Richmond, California) was measured in 13 normal control, 15
nonproteinuric, and 23 proteinuric diabetic patients. The immu-
nofluorescent method for IgG allows the measurement of
concentrations as low as 10 p.g/dl and has, in preliminary
experiments in this study, less than 2% cross-reactivity with
light chains. Degradation products of IgG containing heavy
chains could falsely elevate urinary IgG concentrations. Experi-
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Differences between diabetic and normal patients are: a p < 0.001;
b p < 0.005.
ments by others [6, 7] have shown that intact urinary lgG
account for almost 99% of immurloreactivity to a heavy-chain-
specific IgG antibody and have failed to detect lgG fragments in
urine samples from diabetic patients. Plasma concentrations of
albumin, IgG and 2-microg1obulin were measured in all sub-
jects in whom urinary IgG was determined.
Fasting glycosylated hemoglobin, HbA1, [8] was measured in
23 proteinuric and 35 nonproteinuric diabetic patients. In the
proteinuric diabetic patients glomerular filtration rate (0 FR)
was measured by the technique of a single shot injection of 51Cr
EDTA [9, 10]. Plasma glucose concentration was determined by
the glucose oxidase method (Analox, GM5). Excretion rates
were derived from concentration and timed urine volume.
Clearances were calculated by using the formula UV/P and
corrected to 1.73 m2 body surface area. In patients with
declining GFRs [11] protein clearances were divided by the
clearance of 5tCr EDTA to express the fractional clearance.
Statistical analyses were performed by the use of parametric
and nonparametric tests as appropriate. The least squares
method was used for calculation of the correlation coefficient.
Results
Insulin-dependent diabetic patients without proteinuria (Al-
bustix negative). The 24-hr urinary excretion of albumin in 27
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.Patient
no.
Plasma glucose, mmolelliter
CIT CSII P value
1 9.0 5.4 4.0 1.4 <0.001
2 12.8 6.3 8.0 1.7 <0.05
3 10.3 3.8 5.9 1.9 <0.001
4 12.8 4.0 3.6 0.5 <0.001
5 10.2 6.9 6.4 1.9 <0.05
6 11.5 2.4 7.9 2.0 <0.005
7 11.0 5.2 5.6 1.6 <0.005
8 9.5 5.5 5.8 1.7 <0.05
9 7.7 4.1 6.7 1.5 NS
nondiabetic patients and in 80 diabetic patients divided into
three groups according to the duration of diabetes is compared
in Figure 1. The albumin excretion rate was significantly
elevated over normal in each of the diabetic subgroups. Mi-
croalbuminuria above the upper limit of the normal range was
found in 40% (P <0.02) of the diabetic group with less than 10
years' duration, in 46% (P < 0.01) of those with 11 to 20 years'
duration, and in 35% (P < 0.025) in the group with 21 to 30 years
of diabetes.
Figure 2 shows the urinary excretion rates of 32-microglob-
ulin in the same subjects. No statistically significant differences
in mean rates were found between diabetic patients (in each
duration group) and normal controls.
Urinary IgG excretion rates in 13 nondiabetic men (age range,
24 to 55 years; mean, 36 years) and 15 diabetic men (age range,
15 to 52 years; mean, 32.1 years) are shown in Figure 3. No
selection was applied in the choice of these subjects who
represent those entering the study after measurements of !gG
began. Duration of diabetes in the latter group ranged from 2
months to 27 years (mean, 11.7 years). The diabetic patients
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Fig. 4. Relationship between HbA1 and urinary albumin excretion rates
(log scale) in 35 insulin-dependent diabetic patients negative to Albustix(r = 0.73; P < 0.001).
Table 2. Mean plasma glucose SD obtained during a day profile in
nine insulin-dependent diabetic men on CIT and on CSII
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Fig. 5. Correlation between HbA1 and urinary excretion of lgG (log
scale) in 13 insulin-dependent diabetic men negative to Albustix (r =
0.69; P < 0.01).
had a significantly higher mean urinary excretion rate of IgG (P
< 0.01) than the normals. Calculated clearance rates of albu-
min, IgG, and 32-microglobulin in the 15 insulin-dependent
diabetic and 13 normal patients described above are shown in
Table 1. Mean albumin and IgG clearances were significantly
higher (P < 0.001 and P < 0.005, respectively) in diabetic
patients, but 32-microglobulin clearances did not differ signifi-
cantly. The high correlation (r = 0.73; P < 0.001) between
HbA1 and urinary excretion rates of albumin in 35 insulin-
dependent diabetic patients is illustrated in Figure 4 which
includes all patients in whom both measurements were avail-
able. A similar positive relationship was observed between
HbA1 and IgG (r = 0.69; P < 0.01) in the 13 diabetic men in
whom both measurements were available (Fig. 5). No signifi-
cant correlation was found between HbA, and 32-microglobulin
excretion.
The mean plasma glucose concentrations (± SD) were calcu-
lated from the glycemic profiles in the nine diabetic men who
underwent 3 weeks of CS!! and compared with those during
CIT in Table 2. Blood glucose determinations were made every
2 hr at the same time points on both occasions. In all but one of
the diabetic patients, mean glycemia was significantly higher on
CIT than on CSII. The patient whose mean plasma glucose did
not improve significantly showed, however, much larger glyce-
mic variations on CIT than on CS!! as indicated by the
markedly higher SD.
HbA1 concentration was significantly lower after 3 weeks on
CS!I than after CIT (mean 10.6 0.9%, and 12.3
0.8%, respectively; P < 0.001).
Figure 6 shows the urinary excretion rate of IgG during
ordinary and after strict blood glucose control in these nine
diabetic men. Three weeks of CS!!-induced glycemic correction
markedly reduced the IgG excretion rate (P <0.005), all values
falling then below the upper limit of the normal range. No
changes were seen in the excretion rates of 32-microglobulin.
Insulin-dependent diabetic patients with proteinuria (Albus-
tix pos). Table 3 shows the range and mean values for 51Cr
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EDTA GFR and for urinary excretion of albumin, IgG, and P2-
microglobulin in 23 insulin-dependent diabetic patients with
positive Albustix.
The negative correlation between albumin and IgG clear-
ances, on the one hand, and GFR, on the other, are shown in
Figure 7 (r =
—0.70; P < 0.00 1 for albumin; and r = —0.71; P <
0.001 for IgG). The clearance of IgG increased relatively faster
with the decline in GFR as indicated by the ratio of albumin to
IgG clearance falling from 25 to 7 as GFR declined from 185 to 9
ml/min/1.73 m2. The ratio was calculated by using the slope of
the regression line. The correlation coefficient between albu-
minhlgG ratio and GFR was 0.50 (P < 0.05). Figure 8 shows the
inverse hyperbolic relationship between 32-microglobulin ex-
cretion rate and GFR, [r (for linear correlation) =
—0.61; P <
0.011 with significant elevation of the 32-microglobulin excre-
tion occuring with GFRs below 45 ml/min/l.73 m2.
No significant correlations were found between HbA1 and
albumin or IgG excretion rates and clearances in these protein-
uric diabetic patients.
Twenty-four-hr plasma glucose profiles in five proteinuric
diabetic patients during CIT and after 6 months on CSII (Fig. 9)
show that overall glycemic control was considerably improved,
though not normalized, after CSII when HbA1 (±sEM) had
fallen from 14.0 1.1% on CIT to 9.0 0.3% on CSII (P <
0.01). The mean GFR (±sEM) in these five patients on CIT was
37.8 6.4 ml/min/1.73 m2 (range 23 to 54 ml/min/l.73 m2) and
fell to 31 5.1 ml/min/l.73 m2 (range 19 to 48 ml/min/1.73 m2)
after 6 months on CSII. Systolic BP ranged from 130 to 164 mm
Hg (mean, 147.4 mm Hg) and diastolic from 80 to 96 mm Hg
(mean, 87.2 mm Hg) at the end of the 6 months of CSII. These
values were not significantly different from the arterial pres-
sures on CIT.
Figure 10 shows the fractional clearance of albumin and IgG
in five diabetic patients with proteinuria during ordinary and
after long-term strict glycemic control. The fractional clearance
of albumin and IgG increased in all. The mean changes failed to
achieve statistical significance.
Mean (±sEM) fractional clearance of 2-microglobulin also
increased after 6 months on CSII from 4.4 2.54 X l0- to 3.6
2.5 x 10-2 (P < 0.05).
Discussion
Under ordinary conditions of treatment, insulin-dependent
diabetic patients, without clinical signs of renal impairment,
show an elevated transglomerular flux of large protein mole-
cules like albumin and IgG. The microproteinuria of diabetes
appears glomerular in origin with tubular function well pre-
served as indicated by a normal excretion of 2-microglobulin
1121. The finding of an increased excretion rate of IgG, a larger
but less negatively charged protein than albumin (isolectric
point for IgG 6.4 to 7.2; isolectric point for albumin 4.7),
suggests that hemodynamic determinants play an important role
in the increased filtration of proteins, even though associated
disease-induced changes in the electrostatic negative barrier of
the glomerular capillary wall cannot be excluded [13, 14].
Micropuncture studies in diabetic rats 115, 161 have demonstrat-
ed that the high GFR of diabetes is, at least partly, due to an
increase in glomerular plasma flow and in transcapillary pres-
sure gradient driving forces for the migration of macromol-
ecules across the glomerular wall. No published study has thus
far addressed the question of the role of loss of glomerular fixed
negative charges in determining protein filtration in early
diabetes.
The quality of metabolic control appears to be a powerful
factor in the increased glomerular leakage of proteins in the
preproteinuric stages of diabetes. Correction of hyperglycemia
induces a prompt reversal of the microigGuria as well as of the
microalbuminuria [2, 17, 18]. The promptness of this response
points to some rapidly reversible functional factor(s) responsi-
ble for the microproteinuria. The glomerular surface area
available for filtration is increased early in diabetes, but is not
significantly lessened by 3 to 7 weeks of careful insulin treat-
ment [19]. Reversal of this structural change is therefore
unlikely to account for the observed responses.
After a 'silent' period of many years, persistent proteinuria
appears in approximately 31% of insulin-dependent diabetics
[20], often preceded by a short period of intermittent protein-
uria. Glomerular function as assessed by GFR, which can be
normal or even high at the onset of proteinuria, begins its
progressive decline [21]. Cross-sectional observations made in
this study indicate that in most patients proteinuria remains
glomerular in origin until GFR falls below 45 ml/min/l .73 m2, a
stage at which evidence of tubular dysfunction appears. How-
ever, an increased urinary excretion of p2-microglobulin in the
presence of impaired glomerular function must be interpreted
with caution. A tubular threshold for 32-microglobulin reab-
sorption may exist, and patients with reduced GFR and plasma
levels of 32-microglobulin greater than 5 mg/liter often excrete
large amounts of the protein [22]. Six of our proteinuric patients
had plasma concentrations of f32-microglobulin exceeding 5
mg/liter. Thus, increased urinary excretions of32-microglobulin
may result, rather than from an impairment of tubular function,
from an overspill of the protein into the urine due, probably, to
a protein overload per surviving nephron.
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Fig. 6. Urinary IgG excretion rates, g/min (log scale), in nine insulin-
dependent diabetic men during ordinary and after strict blood glucose
control.
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Fig. 7. Relationship between albumin (I) and IgG (0) clearance (log
scale) and GFR (51Cr EDTA clearance) in 23 insulin-dependent diabetic
patients with proteinuria. The correlation coefficient (albumin) r =
—0.70, P < 0.001; and (lgG) r —0.71, P < 0.001).
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The seiving properties of the glomerular membrane appear to
maintain a degree of selectivity, until the progressive fall in
GFR sets in. The ratio of albumin to IgG clearance fell from 25
to 7 with GFR declining from 185 to 9 ml/min/I.73 m2. Infer-
ences about glomerular seiving property from clearances of
large molecular weight proteins are possible in conditions of
clinical proteinuria on the assumption that, with substantially
increased glomerular filtration of albumin, the tubular reabsorp-
tive mechanism becomes rapidly saturated and nearly all fil-
tered protein is excreted in the urine. Studies in the rat support
this view [23, 24].
Transglomerular transport of neutral dextran in late stage
diabetic nephropathy is restricted [7], suggesting a reduction in
the average size and/or number of pores in the glomerular
membrane. Thus, loss of the electrostatic repulsion component
of the glomerular barrier may well contribute to proteinuria in
clinical diabetic nephropathy. There is evidence from biochemi-
cal studies of kidneys in patients with diabetic nephropathy of
depletion of sialic acid containing glycoproteins, the glomerular
polyanion responsible for the restriction in the filtration of
circulating anionic proteins like albumin [251. However, the
progressive loss of discrimination between molecules of differ-
ent size, with relatively more lgG being filtered, would also
suggest that either discrete large membrane defects [7], or gross
hemodynamic abnormalities occur in the surviving glomeruli.
Alongside completely scierosed glomerular units, large, over-
blown glomeruli are seen in late diabetic nephropathy [261.
These hyperfunctioning units most likely have a greater elevat-
ed transglomerular filtration pressure.
A striking feature of this late clinical proteinuria is that it
bears no evident relationship with blood glucose control; the
pathological process appears to have become independent of
the initiating metabolic disorder. This view is further supported
by the failure of long-term near-normoglycemia to reduce the
fractional clearance of albumin and lgG. At this late stage loss
of nephrons probably triggers a compensatory hyperfunction in
the remaining glomeruli which then enter a vicious downward
spiral of loss-hyperfunction-loss. This process appears to be
200 self-maintaining.
The link between the early, metabolically responsive, micro-
proteinuria on the one hand and the later, heavier, apparently
irreversible, clinical proteinuria on the other is ill-understood.
There is evidence that prolonged leakage may lead to an
accumulation of protein in basement membranes and in the
mesangial region and that this may contribute to the ultimate
development of glomerulosclerosis [27—29]. It is only after a
proportion of glomeruli is lost that clinical proteinuria appears,
the vicious spiral is entered, and the inexorable decline in
overall renal function begins. The microproteinuria which pre-
cedes clinical proteinuria is promptly reversible. If it is indeed
causal its early detection and vigorous treatment might prevent
the development of clinical diabetic nephropathy.
Table 3. GFRs (51Cr EDTA clearance) and urinary excretion rates of albumin (mg124 hr), lgG (mg124 hr) and 2-microglobulin (p.g/24 hr) in 23
insulin-dependent diabetic patients positive to Albustix"
GFR
ml/,ninll.73 m2
Albumin
excretion rate
mg/24 hr
lgG excretion
rate
tng/24 hr
Geometric
mean x/÷ TFb 576 x/÷ 2.1 1129 x/+ 3.1 48 ></÷ 4.7 577.3 x/÷ 6.9
Range (9 to 185) (167 to 5885) (2.5 to 1204) (32 to 38880)
Results are presented as the range of values and the geometric mean x/+.b Tolerance factor (TF) is used because of the positively skewed distributions; TF is the equivalent of SD when geometric means are used. The
tolerance interval is obtained by multiplying or dividing the geometric mean by TF.
[32-microglobulin
excretion rate
ig/24 hr
E
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Fig. 8. Correlation between urinary 132-microglobulin excretion (log
scale) and GFR in 23 insulin-dependent diabetic patients with protein-
uria (r =
—0.61; P < 0.01).
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Fig. 9. Plasma glucose profiles in five insulin-dependent proteinuric
diabetics on ClTandafter6 months on CS!!. Means significantly higher
on CIT at time points indicated by symbols: * = P < 0.05; ** = P <
0.02; *I'(' = P < 0.005.
Summary. The excretion rates of albumin, lgG and 132-
microglobulin were studied in insulin-dependent diabetic pa-
tients with (Albustix positive) and without (Albustix negative)
clinical proteinuria and in a group of nondiabetic controls. In
patients negative for clinical proteinuria, the mean excretion
rate of albumin and IgG was increased but that of 132-microglob-
ulin was normal. HbA1, a measure of excess glycemia, was
positively correlated with both albumin and IgG urinary excre-
tion rates. Vigorous correction of glycemic control significantly
reduced IgG excretion in nine patients. In patients positive for
clinical proteinuria, albumin and IgG clearances were inversely
correlated with GFR. the filtration of IgG increasing relatively
more than that of albumin as GFR declined. A negative
hyperbolic correlation was found between GFR and 132-micro-
globulin excretion. In this group HbA1 was unrelated to excre-
tion rates or clearances of albumin and IgG. In clinically
proteinuric patients, long-term correction of hyperglycemia by
continuous subcutaneous insulin infusion failed to check the
increasing albumin and IgG filtration. The microproteinuria of
diabetes is glomerular in origin, is influenced by prevailing
glycemia, and is reversible by vigorous glycemic control. In the
clinically proteinuric phase, by contrast, selectivity is progres-
sively lost and, as GFR falls, proteinuria becomes of a mixed
glomerular and tubular origin. There is no evident association
with prevailing glycemia, and metabolic near-normalization
does not appear to affect progression over the period of
observation considered. This study suggests that clinical pro-
teinuria denotes the installation of a self-maintaining process,
largely independent of the diabetic metabolic disturbance which
gave rise to it. Prevention of clinical diabetic nephropathy by
metabolic correction may be achievable only in the phase of
early microproteinuria.
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